Skip to content
Save at BioLongevity Labs with code EVERYDAY•Save at S1 Research with code everydaypeptide•Save at Alpha Peptides with code EVERYDAY•Save at Ion Peptide with code EVERYDAY•Save at Solution Peptides with code EVERYDAY15•Save at Atomik Labz with code EVERYDAY25•Save at Next Gen Peps with code EVERYDAY•
Save at BioLongevity Labs with code EVERYDAY•Save at S1 Research with code everydaypeptide•Save at Alpha Peptides with code EVERYDAY•Save at Ion Peptide with code EVERYDAY•Save at Solution Peptides with code EVERYDAY15•Save at Atomik Labz with code EVERYDAY25•Save at Next Gen Peps with code EVERYDAY•
EVERYDAYPEPTIDES
  • Peptides
  • Vendors
  1. Home
  2. Peptides
  3. Klotho

Longevity

Klotho

Klotho is a research-use product carried by vendors we track, grouped under Longevity. For research use only; an editorial review is pending.

PreclinicalResearch use only

About Klotho

Klotho is offered by one or more vendors we track. We have not yet written a detailed editorial summary for this compound. The offerings below reflect what vendors currently carry. For research use only — verify dosing, handling, and safety against primary sources.

Category
Longevity
Typical dose
--
Vial sizes
--
Half-life
--
Administration
--
Goals
Longevity

Where to buy

Vendor offerings

Some links on this page are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.

  • Klotho (alphaKlothoLR) (20mcg) from BioLongevity Labs
    BioLongevity LabsTested

    Klotho (alphaKlothoLR) (20mcg)

    $499.00

    $24950.00/mg · 20mcg

    EVERYDAY
    Shop on BioLongevity Labs

Evidence level

Preclinical only

An aging-suppressor protein discovered in 1997, named after the Greek fate who spins the thread of life. Endogenously secreted by kidney and brain; loss-of-function shortens lifespan and gain-of-function extends it in mice. Human therapeutic delivery is in early research.

Mechanism

Mechanism not yet documented.

Researched benefits

  • Aging-suppressor activity (preclinical)

    Mice overexpressing klotho live ~30% longer; klotho-null mice show accelerated aging, vascular calcification, and early death. The protein is one of the most-replicated longevity genetic interventions in mammals.

  • Cognitive enhancement signal

    Mice with elevated klotho show improved hippocampal function and resilience to neurodegeneration models. In humans, the KL-VS heterozygous variant (~25% of population) is associated with better cognitive performance and lower dementia risk in observational cohorts.

  • Phosphate and FGF23 axis regulation

    Klotho is the obligate co-receptor for FGF23, central to phosphate homeostasis. Renal disease causes klotho deficiency, which contributes to vascular calcification and accelerated aging in CKD patients — the strongest human disease association.

  • Theoretical kidney and vascular protection

    Animal models of CKD and vascular disease show benefit from klotho restoration via gene therapy or recombinant protein. Translation to humans is at the proof-of-concept stage.

Risks & cautions

  • high

    Identity and purity ambiguity

    Native klotho is a 1012-amino-acid type I transmembrane protein with a large soluble ectodomain (~130 kDa). It is too large to be a typical research peptide. Products sold as 'klotho' on peptide markets are often fragments, mimetic peptides, or of unverified identity. Be skeptical.

  • moderate

    Pharmacokinetic mismatch

    A full-length recombinant klotho protein requires specialized expression systems and cold-chain handling. Vials sold at typical research-peptide prices are unlikely to contain intact bioactive protein at meaningful concentration.

  • moderate

    Phosphate homeostasis disruption

    Klotho potentiates FGF23 signaling, which lowers serum phosphate by promoting renal excretion. Sustained supraphysiologic dosing could theoretically produce hypophosphatemia, though no human data exists.

  • high

    Limited safety dataset

    No approved klotho therapeutic exists. Human exposure is limited to investigational settings. Long-term safety is uncharacterized.

Dosing

No standardized research-peptide protocol. Vendor-listed doses (typically microgram range subcutaneously) are not supported by clinical data.

Conservative
No evidence-based dose exists
Standard
No evidence-based dose exists
Aggressive
No evidence-based dose exists

Vial sizes

--

Half-life

--

Route

--

Treat any 'klotho' research product with extra skepticism. Independent third-party purity and identity verification (mass spectrometry) would be advisable before use. Storage as full-length protein requires deep freeze; typical lyophilized peptide vials are unlikely to preserve activity if the product is actually full-length klotho.

Contraindications

  • Hypophosphatemia or hyperphosphaturic syndromes
  • Active malignancy (theoretical, given proliferative effects on some tissues)
  • Pregnancy or breastfeeding — no data
  • Chronic kidney disease stage 4–5 without nephrology supervision

In depth

Background

Klotho was discovered in 1997 by Makoto Kuro-o and colleagues. A mouse strain with a defective klotho gene showed a striking phenotype — short lifespan, infertility, vascular calcification, osteoporosis, skin atrophy — that recapitulated multiple aspects of accelerated aging. The gene was named after Klotho, one of the three Fates of Greek mythology.

The 2005 follow-up (Kurosu et al., Science) showed that overexpression of klotho extended mouse lifespan by ~20–30%, making it one of the cleanest single-gene longevity interventions in mammals.

Klotho exists in two forms:

  1. Membrane-bound klotho (transmembrane) — primarily in kidney and choroid plexus; functions as obligate co-receptor for FGF23.
  2. Soluble klotho (s-klotho) — the ectodomain shed by ADAM10/17, circulates in blood and CSF, and has independent signaling activity as an aging-suppressor.

For research-peptide purposes, soluble klotho or its α-Klotho subdomain (KL1, KL2) is the conceptual target. The molecule's size (~130 kDa for the soluble form) places it well outside the typical "research peptide" category.

Mechanism in depth

Klotho's signaling is multifaceted:

  1. FGF23 co-receptor activity. Membrane klotho is required for high-affinity FGF23 binding to FGFR1c, regulating renal phosphate handling and vitamin D activation.
  2. IGF-1 / insulin pathway modulation. Soluble klotho inhibits IGF-1 signaling, with downstream FOXO activation — a canonical longevity pathway shared with C. elegans daf-2 mutants.
  3. Wnt pathway inhibition. Klotho binds and modulates Wnt ligands, suppressing aberrant Wnt signaling that contributes to stem cell exhaustion and aging.
  4. TGF-β pathway suppression. Reduces fibrotic signaling in kidney, vasculature, and other tissues.
  5. NMDA receptor enhancement in CNS. Underlies the cognitive enhancement signal in mouse and possibly human observational data.

The breadth of these pathways is part of what makes klotho both compelling and pharmacologically difficult — it is not a single-receptor agonist.

Human evidence

Human data is observational and indirect:

  • KL-VS heterozygotes (~25% of population) carry a klotho variant associated with higher circulating klotho, modestly improved cognitive performance in older adults, and reduced dementia incidence in several large cohorts.
  • Chronic kidney disease patients have markedly low klotho levels, which track with vascular calcification, cognitive decline, and mortality. This is the strongest disease association.
  • No approved klotho therapeutic exists. Early-phase work on recombinant klotho or klotho-derived peptides has been published but has not yet reached pivotal trials.

Animal evidence

Extensive and consistent. Overexpression extends lifespan in mice; knockout produces accelerated aging; soluble klotho administration improves cognition in aged mice and disease models; klotho restoration in CKD models protects vasculature and kidney function. Effects replicate across labs.

Stack synergy

There is no established clinical stack. Mechanistically interesting combinations would include:

  • Rapamycin/sirolimus — both modulate longevity pathways (mTOR and IGF-1) but no formal interaction work.
  • Senolytics (e.g., dasatinib + quercetin) — share the broad anti-aging conceptual framework.
  • NAD+ precursors — common in longevity stacks; mechanistic overlap is limited.

Because actual klotho protein supply is uncertain at the research-peptide level, real-world stacks involving "klotho" should be interpreted with caution about what the user is actually receiving.

Open questions

  • Can soluble klotho (or a klotho-derived peptide) actually be delivered as a research-peptide-style subcutaneous injection with sustained bioactivity? The molecular weight and stability profile suggest this is non-trivial.
  • Which sub-region of klotho (KL1, KL2, or specific peptides within) is responsible for which downstream effects? Pinning this down would enable small-peptide mimetics that are pharmacologically tractable.
  • Does klotho exposure raise any cancer risk through its growth-factor modulation effects? Mouse longevity data is reassuring, but specific oncology contexts are not fully explored.
  • What is the actual identity and purity of products sold as "klotho" by research peptide vendors? Independent characterization is needed before pharmacological claims are credible.

References

  1. 1.Kuro-o M. et al. — Mutation of the mouse klotho gene leads to a syndrome resembling ageing (Nature, 1997)
  2. 2.Kurosu H. et al. — Suppression of aging in mice by the hormone Klotho (Science, 2005)
  3. 3.Dubal D.B. et al. — Life extension factor klotho enhances cognition (Cell Reports, 2014)
  4. 4.Hu M.C. et al. — Klotho and kidney disease (Journal of Nephrology, 2010)

Everyday Peptides

Independent peptide guides and vendor comparison. Research-grade information for adult researchers.

Browse

  • All peptides
  • All vendors

About

  • About us
  • Contact

Legal

  • Affiliate disclosure
  • Privacy

(c) 2026 Everyday Peptides. Some links on this site are affiliate links. We may earn a commission when you purchase through them, at no extra cost to you.

All content is for educational purposes only and is not medical advice. Peptides discussed are for research use only.